Abstracts tagged "Cardiovascular disease"

Abstract Number: 930 • 2016 ACR/ARHP Annual Meeting
How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁶, Glenn Haugeberg⁷ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Martina Hansens Hospital, Bærum, Norway
Background/Purpose: The EULAR recommendations for cardiovascular disease (CVD) risk management in patients with inflammatory joint diseases (IJD) states that CVD risk assessment should be considered…
Abstract Number: 1482 • 2016 ACR/ARHP Annual Meeting
Web-Based PILOT Intervention Study to Improve Cardiovascular Risk Knowledge Among Rheumatoid Arthritis Patients
Meenakshi Jolly¹, Eleftheria Steinig², Lisa Walt³ and Rasa Kazkauskaite⁴, ¹Rush, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rush University, Chicago, IL, ⁴Rush University, chicago, IL
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA), underscoring the importance of CVD prevention. The rates of screening and…
Abstract Number: 1993 • 2016 ACR/ARHP Annual Meeting
The Risk of Stroke in Patients with Rheumatoid Arthritis and the Association with Competing Adverse Events
Yvette Meißner¹, Adrian Richter², Joern Kekow³, Hans Peter Tony⁴, Elke Wilden⁵, Angela Zink^6,7, Joachim Listing² and Anja Strangfeld⁷, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, ⁴Rheumatology / Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ⁵Rheumatologist, Köln, Germany, ⁶Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁷Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for infections, hospitalizations and cardiovascular (CV) events. The association of serious adverse events (SAE) with…
Abstract Number: 2599 • 2016 ACR/ARHP Annual Meeting
TCZ Improves the Pro-Atherothrombotic Profile of Rheumatoid Arthritis Patients Modulating Endothelial Dysfunction, Netosis and Inflammation
Patricia Ruiz-Limon¹, Rafaela Ortega-Castro², IVÁN ARIAS DE LA ROSA², Carlos Perez-Sanchez², Yolanda Jiménez-Gómez², Maria Carmen Abalos-Aguilera¹, Pilar Font-Ugalde², Eduardo Collantes-Estévez², Alejandro Escudero-Contreras², Chary Lopez-Pedrera² and Nuria Barbarroja², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: Inhibition of the interleukin IL-6 receptor pathway by tocilizumab (TCZ) is an effective treatment for rheumatoid arthritis (RA). TCZ reduces atherosclerosis markers and improves endothelial function.…
Abstract Number: 419 • 2016 ACR/ARHP Annual Meeting
Performance of Framingham Risk Factor Score in Predicting Cardiovascular Events in Patients with Polymyalgia Rheumatica
Florencia Beatriz Mollerach¹, Sebastian Moyano¹, Luciano Enrique Pompermayer¹, Jose Maximiliano Martinez Perez², Marina Scolnik³, Javier Rosa¹, Luis J. Catoggio⁴ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, Internal Medicine Service, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ³Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina
Background/Purpose: chronic inflammatory diseases are at a substantially increased risk of cardiovascular disease. Framingham risk score (FRS) underestimates cardiovascular risk in many inflammatory diseases. Our…
Abstract Number: 931 • 2016 ACR/ARHP Annual Meeting
Rates of Lipid Testing and Statin Prescriptions Among SLE and Diabetes Mellitus Patients in a Nationwide Medicaid Cohort
Sarah K. Chen¹, Medha Barbhaiya², Michael A. Fischer³, Hongshu Guan⁴, Tzu-Chieh Lin², Candace H. Feldman⁵, Brendan M. Everett⁶ and Karen H. Costenbader², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA, ⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: We have recently found that rates of myocardial infarction (MI) are similar among individuals with SLE and those with diabetes mellitus (DM) in a…
Abstract Number: 1483 • 2016 ACR/ARHP Annual Meeting
Elevated Anti-Cyclic Citrullinated Peptide Antibody Titer Is Associated with Increased Cardiovascular Risk
Sarah A. Fantus¹, Melissa R. Bussey², Rochella A. Ostrowski³, Andrew Heisler¹ and Kyle Carey⁴, ¹Internal Medicine, Loyola University Medical Center, Maywood, IL, ²Division of Allergy, Immunology, and Rheumatology, Loyola University Medical Center, Maywood, IL, ³Rheumatology, Loyola University Medical Center, Maywood, IL, ⁴Clinical Research Office, Loyola University Chicago, Maywood, IL
Background/Purpose: Rheumatoid arthritits (RA) patients have an increased risk of mortality from cardiovascular (CV) disease. Proposed adaptation of CV risk score models in RA patients…
Abstract Number: 2051 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Cardiovascular Disease Predate the Onset of Symptoms of Rheumatoid Arthritis
Heidi Kokkonen¹, Lisbeth Ärlestig² and Solbritt Rantapää-Dahlqvist^3,4, ¹Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁴Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular (CV) comorbidity compared with the general population. Contradictory results concerning CV disease…
Abstract Number: 2633 • 2016 ACR/ARHP Annual Meeting
Effect of Different Biologic Agents on Lipid Profile in Rheumatoid Arthritis
Fabio Cacciapaglia¹, Simone Perniola¹, Mariangela Nivuori¹, Margherita Giannini¹, Olga Magazzino¹, Maria Giannotta¹, Florenzo Iannone² and Giovanni Lapadula¹, ¹Interdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, General Hospital, Bari, Italy, ²Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, General Hospital, Bari, Italy
Background/Purpose: o examine any change between different biologic agents on lipid profile of RA patients. Methods: Patients affected by RA, according to the 2010 EULAR/ACR…
Abstract Number: 420 • 2016 ACR/ARHP Annual Meeting
Feasibility of a Rheumatology Staff Protocol for Tobacco Cessation Counselling and Quit Line Electronic Referral
Christie M. Bartels¹, Daniel Panyard², Diane Lauver³, Emmanuel Sampene⁴, Zhanhai Li⁵, Robert Adsit⁶, Patrick McBride⁷, Heather Johnson⁷, Kristin Steffen Lewicki⁸ and Edmond Ramly⁹, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin-Madison School of Nursing, Madison, WI, ⁴Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI, ⁷Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁸Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁹Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI
Background/Purpose: Smoking is a both a risk factor for developing rheumatoid arthritis (RA) and a predictor of severe, treatment-refractory disease in RA and other rheumatic…
Abstract Number: 973 • 2016 ACR/ARHP Annual Meeting
Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Jessica K. Gordon¹, Jackie Szymonifka², Matthew R. Lammi³, Virginia D. Steen⁴ and PHAROS Investigators, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients (pts) with Systemic Sclerosis (SSc). The World Health Organization (WHO) classifies PH into…
Abstract Number: 1484 • 2016 ACR/ARHP Annual Meeting
Exploring the Link Between RA Disease Activity, Lipid Levels, and Cardiovascular Disease in an Early Inflammatory Arthritis Cohort
Saurash Reddy, Xiaobo Meng and Carol Hitchon, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid arthritis (RA) has been established as a risk factor for cardiovascular disease (CVD), with systemic inflammation being linked with atherosclerosis. Traditional CVD risk…
Abstract Number: 2055 • 2016 ACR/ARHP Annual Meeting
Myocardial Abnormalities Are Associated with Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms Assessed Using Cardiac Magnetic Resonance Imaging
Yasuyuki Kobayashi¹, Hitomi Kobayashi², Atsuma Nishiwaki³, Kaita Sugiyama³, Yosuke Nagasawa⁴, Takamasa Nozaki², Noboru Kitamura⁵, Masami Takei⁴, Natsumi Ikumi⁶ and Hirotake Inomata³, ¹Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ²Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Nihon University School of Medicine, Tokyo, Japan, ⁴Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁵Hematology and Rheumatology, NIhon University School of Medicine, Tokyo, Japan, ⁶Nihon University School of Medicine, Shinjuku, Japan
Background/Purpose: Individuals with rheumatoid arthritis (RA) have two-fold higher risk of sudden death than age- and sex-matched controls without RA. We hypothesized that myocardial abnormalities…
Abstract Number: 2866 • 2016 ACR/ARHP Annual Meeting
Lupus HDL Induces Pro-Inflammatory Responses in Macrophages By Binding LOX1Rand Failing to Promote ATF3 Activity
Carolyne K. Smith¹, Nickie Seto¹, Anuradha Vivekanandan-Giri², Wenmin Yuan³, Martin Playford⁴, Zerai G. Manna⁵, Sarfaraz A. Hasni⁶, Rui Kuai³, Nehal N. Mehta⁴, Anna Schwendeman³, Subramaniam Pennathur² and Mariana Kaplan⁷, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Internal Medicine/Nephrology, University of Michigan Nephrology, Ann Arbor, MI, ³Department of Medicinal Chemistry and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, ⁴NHLBI, National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶Lupus Clinical Research Program, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁷NIAMS/NIH, Bethesda, MD
Background/Purpose: Recent evidence indicates that high-density lipoprotein (HDL) exerts vasculoprotective activities by promoting activating transcription factor 3 (ATF3), leading to down-regulation of TLR-induced inflammatory responses.…
Abstract Number: 421 • 2016 ACR/ARHP Annual Meeting
Educating Patients on the Cardiovascular Risks of Rheumatoid Arthritis: Usual Care Versus a Structured Approach
Marcia Genta¹ and Robert M. Genta², ¹Dallas Arthritis Center, Dallas, TX, ²Laboratory, Dallas Arthritis Center, Dallas, TX
Background/Purpose: Rheumatoid Arthritis (RA) carries a considerable increase of the risks for cardiovascular (CV) disease. It is unclear how well patients with RA understand such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].